Within 6 feet of confirmed or suspected COVID-19–positive person for >15 minĪny exposure group within 5 days of exposure c Living with confirmed or suspected COVID-19–positive person The specificity was 99% for symptomatic participants and >99% for asymptomatic participants among all exposure groups. Among asymptomatic participants, the positive predictive value was 90% (95% CI 80%, 96%), and among symptomatic participants the positive predictive value was 95% (95% CI 90%, 98%) ( Table 2). The sensitivity of the rapid antigen test was higher in symptomatic participants (87% 95% CI 80%, 91%) than for asymptomatic participants (71% 95% CI 61%, 80%) ( P 15 min of someone with confirmed or suspected COVID-19 100% (95% CI 70%, 100%) for those who reported any other exposure and 64% (95% CI 51%, 76%) for those who reported being unexposed. government invested more than $800 million to increase the production of point-of-care tests, such as rapid antigen tests ( 1, 6). Food and Drug Administration for clinical use in symptomatic individuals, and three have been approved for home use ( 4, 5). Fourteen brands of such tests have received emergency use authorization by the U.S. Rapid lateral flow antigen (herein, “rapid antigen”) tests detect viral proteins and many have a 15-min turnaround time for results, which can enable individuals who test positive to quickly self-isolate to prevent transmission and can accelerate assessment of individuals at high risk for severe COVID-19 for possible monoclonal antibody treatment. According to a large, nationally representative survey sample, median test result wait times are longer for African Americans (5 days) and Hispanic Americans (4.6 days) compared with white Americans (3.9 days) ( 3). However, such testing can take more than 48 h to yield results ( 3). Reverse transcription–PCR (RT-PCR) remains the “gold standard” for identifying infected individuals ( 2). Nonetheless, rapid antigen testing quickly identifies positive among those with symptoms and/or close contact exposure and could expedite isolation and treatment. BinaxNOW has high accuracy among symptomatic individuals and is below the FDA threshold for emergency use authorization in asymptomatic individuals. Specificity was greater than 99% for all groups. Sensitivity was 82% (95% CI 66%, 91%) for asymptomatic individuals with potential exposure and 64% (95% CI 51%, 76%) for those with no exposure. It was higher in symptomatic (87% 95% CI 80%, 91%) than asymptomatic (71% 95% CI 61%, 80%) individuals. Overall test sensitivity compared with reference laboratory reverse-transcription PCR testing was 81% (95% confidence interval 75%, 86%). Most (89%) were asymptomatic, of whom 17% reported potential exposure. Participants were grouped by self-reported COVID-19 exposure and symptom status. We describe our implementation and assess performance of the BinaxNOW COVID-19 Antigen Test (Abbott Laboratories) in 6,099 adults at a self-referred walk-up testing site. Rapid antigen tests are simple to perform and provide results within 15 min.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |